Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified

Experimental Hematology & Oncology - Tập 10 Số 1 - 2021
Kaiqi Liu1, Yan Li1, Shaowei Qiu1, Chunlin Zhou1, Shuning Wei1, Dongxin Lin1, Guangji Zhang1, Hui Wei1, Ying Wang1, Bingcheng Liu1, Xiaoyuan Gong1, Qiuyun Fang1, Yunhu Song1, Huijun Wang1, Chengwen Li1, Qinghua Li1, Lihua Wu1, Bin Gong1, Yuntao Liu1, Jianxiang Wang1, Yingchang Mi1
1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China

Tóm tắt

AbstractAcute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) is a rare type of acute leukemia. Management of relapse/refractory (R/R) patients is still challenging.traditional chemotherapy treatment is not effective. In this paper, we reported 6 R/R patients diagnosed as ALAL-NOS in our hospital, who were treated with venetoclax based treatment (venetoclax combining with azacitidine or chemotherapy). All 6 patients achieved CR. Five of the six patients received allo-HSCT, four patients were still alive in CR until the follow-up day. Our data provide preliminary evidence and show that venetoclax based regimens are effective and safety in patients with R/R ALAL-NOS.

Từ khóa


Tài liệu tham khảo

Hyun GL, Hee JB, Ho SK, Soo MP, Tai JH, Hoon K. Biphenotypic acute leukemia or acute leukemia of ambiguous lineage in childhood: clinical characteristics and outcome. Blood Res. 2019;54:63–73.

Orgel E, Alexander TB, Wood BL, Kahwash SB, Devidas M, Dai YF, et al. Mixed-phenotype acute leukemia: a cohort and consensus research strategy from the children’s oncology group acute leukemia of ambiguous. Lineage Task ForceCancer. 2020;126(3):593–601.

Wolach O, Stone RM. How I treat mixed-phenotype acute leukemia. Blood. 2015;125:2477–85.

Olga ZS, Ninela IJ, Elżbieta D, Katarzyna MR, Maryna KR, Joanna Z, et al. Mixed phenotype acute leukemia: biological profile, clinical characteristic and treatment outcomes: report of the population-based study. Eur J Haematol. 2020;105:85–93.

Tian H, Xu Y, Liu L, Yan L, Jin Z, Tang X, et al. Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone. Leuk Res. 2016;45:40–6.

Shimizu H, Saitoh T, Machida S, Kako S, Doki N, Mori T, et al. Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis. Eur J Haematol. 2015;95:455–60.

Eyre TA, Kirkwood AA, Gohill S, Follows G, Walewska R, Walter H, et al. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. Br J Haematol. 2019;185(4):656–69.

Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–17.

Courtney DD, Keith P, Vinod P,Brian AJ, Martha A, Pamela S, B,et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.

Andrew HW, Pau M, Vladimir I,Courtney DD, Jan N, Kamel L,et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–45.

Chong CC, Andrew WR, John R, Chun YF, Stephen BT, Jessica MS, et al. Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J Clin Oncol. 2020;3(30):3506–17.

Wu X, Zhang J, Chen Q, Zhou L, Li M, Qiu H, et al. Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia. BJH. 2020;189(5):e200-4.

Thông tin
Thông tin xuất bản

Experimental Hematology & Oncology

Tập 10 Số 1

Thông tin tác giả